An Optimized Protocol for the Characterization of Zebrafish ApoB-Containing Lipoproteins Using the LipoGlo System

Apolipoprotein B-containing lipoproteins (ApoB-LPs) transport lipids throughout the circulation and are closely associated with cardiovascular disease in humans. Many aspects of ApoB-LP biology remain elusive, often due to their indirect characterization through the measurement of plasma triglycerides and cholesterol. The conventional approach provides limited information on ApoB-LPs number and size distribution, essential features that influence cardiovascular disease risk. Additionally, drug studies have historically been limited to the use of mammalian research models, which are not suited for high-throughput experiments. Therefore, we generated a reporter system (LipoGlo) utilizing a luciferase enzyme (NanoLuc) fused to the C-terminus of the zebrafish (Danio rerio) ApoBb.1 protein. In metazoans, ranging from insects to humans, each ApoB-LP contains a single ApoB molecule, such that the luminescence emitted from these transgenic fish is proportional to the total number of ApoB-LPs. The LipoGlo zebrafish reporter generates a quantitative chemiluminescent signal that can be used in plate-based assays to measure lipoprotein quantities, a gel-based assay that can measure lipoprotein size distribution, and chemiluminescent microscopy that can, for the first time, visualize lipoprotein localization in a larval zebrafish. LipoGlo, combined with the amenability of zebrafish to genetic approaches, facilitates the rapid assessment of any gene or drug's role in ApoB-LP molecular and cell biology. This protocol describes three optimized LipoGlo assays that facilitate ApoB-LP characterization with 100× less starting material than prior assays routinely used for mammalian lipoprotein analysis. Key features • Improves upon the methods from Thierer et al. [1]. • Lipoprotein profiles from individual zebrafish larvae that can simultaneously be genotyped for specific mutations.